saframycin S
N-[(1,5,6,7,9,10,13,14,14a,15-Decahydro-7-hydroxy-2,11-dimethoxy-3,12,16-trimethyl-1,4,10,13-tetraoxo-6,15-epimino-4H-isoquino[3,2-b][3]benzazocin-9-yl)methyl]-2-oxopropionamide
Saframycin S is an antibiotic with a racemomycin group that exhibits inhibitory activity against Ehrlich ascites tumors. The LD50 of Saframycin S in ddY mice is 3.2 mg/kg (i.p.)[1].
References
[1] Mikami Y, et al. Saframycin S, a new saframycin group antibiotic. J Pharmacobiodyn. 1981 Apr;4(4):282-6. DOI:10.1248/bpb1978.4.282
